Last €53.00 EUR
Change Today 0.00 / 0.00%
Volume 0.0
ABBV On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
As of 9:05 AM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1 North Waukegan Road

North Chicago, IL 60064

United States

Phone: 847-932-7900

Fax:

AbbVie Inc. operates as a research-based biopharmaceutical company worldwide. The company develops and markets advanced therapies that address complex and serious diseases. The company’s products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease, cystic fibrosis, and other health conditions. Its pipeline of promising new medicines includes approximately 20 compounds or indications in Phase II or Phase III development across such major medical specialties as immunology, virology, oncology, renal disease, neurological diseases, and women's health. Products HUMIRA HUMIRA is a biologic therapy administered as a subcutaneous injection. It is approved to treat various autoimmune diseases in the United States, Canada, and Mexico (collectively, North America), and in the European Union. HUMIRA is also approved in approximately 60 other markets, including Japan, Brazil, and Australia. The company continues to dedicate research and development efforts to expanding indications for HUMIRA, including in the fields of rheumatology (pediatric enthesitis related arthritis), gastroenterology (pediatric Crohn's disease and pediatric ulcerative colitis), dermatology (pediatric psoriasis and hidradenitis suppurativa), and ophthalmology (uveitis). Phase III trials are ongoing in preparation for regulatory applications for uveitis and hidradenitis suppurativa in the United States and the European Union. The company works on HUMIRA formulation and delivery improvements to improve convenience and the overall patient experience. Metabolics/Hormones Products Metabolic and hormone products target various conditions, including hypothyroidism, testosterone deficiency, and exocrine pancreatic insufficiency. These products comprise: Synthroid: Synthroid is used in the treatment of hypothyroidism. AndroGel: AndroGel is a testosterone replacement therapy for males diagnosed with low testosterone that is available in two strengths, 1 percent and 1.62 percent. Creon: Creon is a pancreatic enzyme therapy for exocrine pancreatic insufficiency, a condition that occurs in patients with cystic fibrosis, chronic pancreatitis, and various other conditions. The company has the rights to sell Synthroid, AndroGel, and Creon in the United States. Virology Products The company’s virology products include two products for the treatment of HIV infection, Kaletra and Norvir. Kaletra: Kaletra (also marketed as Aluvia in emerging markets) is a prescription anti-HIV-1 medicine that contains two protease inhibitors: lopinavir and ritonavir. Kaletra is used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1. Norvir: Norvir (ritonavir) is a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Endocrinology Products Lupron (also marketed as Lucrin and Lupron Depot) is a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron is approved for daily subcutaneous injection and one-month, three-month, four-month, and six-month intramuscular injection. Dyslipidemia Products The company’s dyslipidemia products address the range of metabolic conditions characterized by high cholesterol and/or high triglycerides. TriCor and TRILIPIX are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, and to increase HDL cholesterol levels. Niaspan is an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, and to increase HDL cholesterol levels. These products are primarily marketed to primary care physicians. Other Products The company’s other products include the following: S

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:FP €53.00 EUR 0.00

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $164.72 USD +2.48
AstraZeneca PLC 4,721 GBp +60.50
Bristol-Myers Squibb Co $58.86 USD +0.34
Eli Lilly & Co $67.32 USD +0.47
Novo Nordisk A/S kr269.70 DKK +2.70
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 29.2x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.